Brain metastasis and the carcinoembryonic antigen;Metástasis cerebrales y antígeno carcinoembrionario

Revista de Neurologia

Volumn 38, Issue 3, 2004, Pages 267-270

  Noris Garcia E ^a,b   Escobar Perez X ^a  

^a INSTITUTO NACIONAL DE ONCOLOGÍA Y RADIOBIOLOGÍA   (Cuba)

^b NONE   (Cuba)

Author keywords

Carcinoembrionary antigen; Cerebral metastasis; Cerebrospinal fluid; Tumor marker

Indexed keywords

CARCINOEMBRYONIC ANTIGEN; IMMUNOGLOBULIN A; TUMOR MARKER;

BLOOD BRAIN BARRIER; BRAIN METASTASIS; CANCER STAGING; CAUSE OF DEATH; CENTRAL NERVOUS SYSTEM TUMOR; CEREBROSPINAL FLUID; CLINICAL FEATURE; DISEASE ASSOCIATION; HUMAN; MOLECULAR WEIGHT; MORTALITY; NEUROLOGIC DISEASE; QUALITY OF LIFE; REVIEW; SYSTEMIC CIRCULATION;

EID: 17444444253     PISSN: 02100010     EISSN: None     Source Type: Journal    
DOI: 10.33588/rn.3803.2003199     Document Type: Review

References (46)

1. Fernández L, Galán Y, Camacho R, Álvarez ME, Landrove O, Antillas M, et al. Registro Nacional de Cáncer. La Habana: CUBACEL. Instituto Nacional de Oncología y Radiobiología; 2001.
2. Louis D, Cavince W. Metastasis brain cancer. In De Vita V, Helmore S, Rosemberg S, eds. Cancer. Principles of oncology. Philadelphia: Lippincott-Raven; 2000. p. 2655-67.
3. Priett A. Neuro Oncology. In Stein JH, ed. Internal medicine. Mosby-Year Book; 1994. p. 1161-70.
4. Uchitomi Y, Mikami I, Kugaya A, Mikamil I, Akizuki N, Nagai K, et al Depression after successful treatment for nonsmall cell lung carcinoma. Cancer 2000; 89: 1172-9.
5. Álvarez R. Afecciones respiratorias más frecuentes en Cuba. In: Temas de medicina general integral. La Habana: Ciencias Médicas; 2001. p. 505.
6. Massot-Punyet R, Almajano J, Camacho JM. Metástasis cerebral. Rev Neurol 2000; 31: 1242-7.
7. Humphrey EW, Ward MB, Peri RT. Cáncer de pulmón en oncología clínica. 2 ed. Washington DC: OPS; 1996. p. 249-65.
8. Law A, Karp DD, Dipetrillo T, Daly BT. Emergence of increased cerebral metastasis after high-dose preoperative radiotherapy with quimotherapy in patients with locally advanced nonsmall cell lung carcinoma. Cancer 2001; 92: 160-4.
9. Andre F, Grunenwald D, Pujol JL, Girard P, Dujon A, Brouchet L, et al. Patterns of relapse of N2 nonsmall-cell lung carcinoma patients treated with preoperative chemotherapy: should prophylactic cranial irradiation be reconsidered? Cancer 2001; 91: 2394-400.
10. Yang GY, Mattews RH. Prophylactic cranial irradiation in small cell lung cancer. Oncologist 2000; 5: 293-8.
11. Robnett TJ, Machtay M, Stevenson JP, Algazi KM, Hahn SM. Factor affecting the risk of brain metastases after definitive chemoradiation for focal advance non-small lung cancer. J Clin Oncol 2001; 19: 1344-9.
12. Pottgen C, Stuschke M. The role of prophylactic in the treatment of lung cancer. Lung Cancer 2001; 33: S153-8.
13. Mateos BF, Simón de la Heras R. Complicaciones neurológicas del cáncer sistémico. Rev Neurol 2002; 35: 285-90.
14. Baiges JJ, Huerta M. Carcinomatosis meníngea. Rev Neurol 2000; 31: 1237-41.
15. Gold P, Freedman S. Demonstration of tumor specific antigens in human colonic carcinoma by immunologic tolerance and absorption technique. J Exp Med 1965; 121: 439-62.
16. Barba-Evia JR. Marcadores tumorales. Revista Mexicana de Patología Clínica 1996; 44: 177-82.
17. Gómez DE, Alonso DF. Marcadores tumorales. In Gómez DE, Alonso DF, eds. Introducción a la oncología molecular. Buenos Aires: Universidad Nacional de Quilms; 1998. p. 147-57.
18. Mitchell EP. Role of carcinoembrionic antigen in the management of advanced colorectal cancer. Semin Oncol 1998; 25: 12-20.
19. Goldenberg DM, Abdel-Nabi H, Sullivan LC, Serafine A, Seldin D. Carcinoembryonic antigen immunoscintigraphy complements mammography in the diagnosis of breast carcinoma. Cancer 2000; 1: 104-15.
20. Karpem MS, Kelsen DP, Tepper J. Cancer of the stomach. In De Vita V, Helmore S, Rosemberg S, eds. Cancer. Principles of oncology. Philadelphia: Lippincott-Raven; 2001. p. 1092-123.
21. Fong L, Hood Y, Rivas A, Benike C. Altered peptide ligand vaccination with FLT3 ligand expanded dendrict cell for tumor immunotherapy. Proc Natl Acad Sci U S A 2001; 98: 8809-14.
22. Nazli O, Bozdag AD, Tansug T, Kir R, Kaymak E. The diagnostic importance of CEA and CA19-9 for the early diagnosis of pancreatic carcinoma. Hepatogastroenterology 2000; 47: 1750-2.
23. Macdonald JS. Carcinoembryonic antigen screening: pros and cons. Sem Oncol 1999; 26: 556-60.
24. Mulcahy MF, Benson III AB. The role of carcinoembryonic antigen monitoring in management of colorectal cancer. Curr Oncol Resp 1999; 2: 168-72.
25. Días M, Rollon M, Muguerza JM, Duce AM, Álvarez MJ. Time dependency of the prognostic effect of carcinoembrionic antigen and p53 protein in colorectal adenocarcinoma. Cancer 2000; 88: 35-41.
26. Hotta K, Segawa Y, Takigawa N, Kisshino N, Saeki H, Nakata M, et al. Evaluation of the relationship between serum carcinoembryonyic antigen and treatment outcome in surgically resected clinical stage I patients with nonsmall lung carcinoma. Anticancer Res 2000; 20: 2177-80.
27. Tas F, Aydiner A, Topus E, Yasasever U, Karadeniz A, Saip P. Utility of the serum tumor marker CYFRA, CEA, and squamous cell carcinoma antigen in squamous lung cancer. J Exp Clin Cancer Res 2000; 19: 477-81.
28. Takamoc K. Clinical predictor of N2 disease in nonsmall lung cancer. Chest 2000; 117: 1577-82.
29. Shung S, Fang J, Chuan S, Jen Y. Tissue polypeptid specific antigen for early prediction in lung adenocarcinoma. Am J Oncol 2000; 236: 605-8.
30. Icard P, Regnard JF, Essomba A, Panebianco U, Magdeleinat P, Lavasseur P. Preoperative carcinoembrionic antigen level as a prognostic indicator in resected primary lung cancer. Ann Thorac Surg 1994; 58: 811-4.
31. Horig H, Lee DS, Conkright W, Divito J, Hasson H, La Mare M, et al. Phase I clinical trial of recombinant canarypoxvirus (ALVAC) vaccine expressing human carcinoembrionic antigen and the B7 co-stimulatory molecule. Cancer Immunol Immunother 2000; 49: 504-14.
32. Jiang XP, Yang DC, Elliot RL, Head JF. Vaccination with a mixed vaccine of autogenous and allogenic breast cancer cell and tumor associated antigens CA15-3, CEA and CA125 results in immune and clinical response in breast cancer patients. Cancer Biother Radiopharm 2000; 15: 495.
33. Song K, Chang Y, Prud'Homme GJ. IL-12 plasmid-enhanced DNA vaccination against carcinoembrionic antigen (CEA) studied in immune-gene knockout mice. Gene Ther 2000; 1527-35.
34. Hill ME, Ellison EC, Hunt WE. Carcinoembryonic antigen in cerebrospinal fluid of adult brain-tumor patients. J Neurosurg 1980; 53: 627-32.
35. Nakagawa H, Kubo S, Murasawa A, Nakajima S, Nakajima Y, Izumoto S, et al. Measurements of CSF biochemical tumor markers in patients with meningeal carcinomatosis and brain tumor. J Neurooncol 1992; 12: 111-20.
36. Uchihara T, Kondo H, Tsuchiya K, Kosaka K, Shimo M, Tsugu A, et al. Marked elevation of carcinoembryonic antigen and carbohydrate antigen 19-9 in the peripheral blood as an initial manifestation of meningeal carcinomatosis. Intern Med 1994; 33: 547-9.
37. Twijnstra A, Ongerboer de Visser BW, Van Zanten AP, Hart AA, Nooyen WJ. Serial lumbar and ventricular cerebrospinal fluid biochemical marker measurements in patients with leptomeningeal metastases from solid and hematological tumors. J Neurooncol 1989; 7: 57-63.
38. Yoshida M, Oshima Y, Moritaka K, Kuramoto S. Carcinoembryonic antigen in cerebroespinal fluid its diagnostic value in neoplasms of the central nervous system. Kurume Med J 1984; 31: 73-9.
39. Rombos A, Evangelopoulu-Katsiri E, Mariatos P, Katsouyanni K, Papagegorgiou C. Cerebroespinal fluid carcinoembryonic antigen and alpha-fetoprotein in patients with central nervous system neoplasia. Acta Neurol Scand 1988; 77: 440-4.
40. Van Zanjen AP, Twijnstra A, Ongerboer de Visser BW, Van Heerde P, Hart AA, Nooyen WJ. Cerebrospinal fluid tumour markers in patients treated for meningeal malignancy. J Neurol Neurosurg Psychiatry 1991; 54: 119-23.
41. Jacobi C, Reiber H, Felgenhauger K. The clinical relevance of locally produced carcinoembrionic antigen in cerebrospinal fluids. J Neurol 1986; 236: 358-61.
42. Sato Y, Ohta Y, Ohtsuka T, Shoji H, Oizumi K. A case of leptomeningeal carcinomatosis: demonstration of CA19-9 and CEA positive central nervous malignant cells in the CSF and particular elevation of CA19-9 level in the CSF. Rinsho Shinkeigaku 1991; 31: 175-8.
43. Dorta AJ. Reibergrama: elemento esencial en el análisis inmunológico del líquido cefalorraquídeo. Rev Neurol 1999; 28: 996-8.
44. Reiber H, Jacobi C, Felgenhauer K. Sensitive quantitation of carcinoembrionic antigen in cerebrospinal fluids and its barrier dependent differentiation. Clin Chim Acta 1986; 156: 259-69.
45. Reiber H. Dynamics of brain derived proteins in cerebrospinal fluid. Clin Chim Acta 2001; 310: 173-86.
46. Reis-Filho J, Faoro LN, Carrilho C, Bleggi-Torres F, Schmitt F. Evaluation of cell proliferation epidermal growth factor receptor and BEL-2 immunoexpression as prognostic factor for patients with World Health Organization grade 2 oligodendroglioma. Cancer 2000; 88: 862-9.